HEALTH TECHNOLOGY

Homerton Healthcare Chooses Sectra as its Enterprise Imaging Cloud Partner

Homerton Healthcare | June 14, 2022

49e750b9-e5f1-4748-87ed-9a4edf32

Medical imaging technology and cybersecurity provider, Sectra, announced that it has been chosen by Homerton Healthcare NHS Foundation Trust to offer its fully cloud-based enterprise imaging solution. Following the announcement, Sectra will be responsible for the hardware, software, and other aspects of IT for Homerton Healthcare.
 

"Having our new imaging solution as a fully managed cloud service will allow us to shift the focus of our IT staff. Our team will be relieved of IT management responsibilities, which will be a significant benefit. We also expect to see clinical benefits, such as faster access to new features and new technology. Moving to a scalable cloud solution furthers our ambitions for a consolidated cloud system supporting all hospitals in our ICS (Integrated Care System) and is a vital first step towards realizing our collaboration potential in the north east London.

-Niall Canavan, Homerton Director of IT and Systems 

Homerton Healthcare NHS Foundation Trust is a trusted provider of health services for communities in Hackney and surrounding London boroughs. The contract will enable Homerton Healthcare to make the most of Sectra’s cloud service for enterprise imaging.

"Sectra and Microsoft share a dedication to improving healthcare and provide high availability, performance and security. I am excited to leverage our experience of providing enterprise imaging in regional and collaborative settings to help Homerton Healthcare achieve clinical benefits, share workloads, and provide their clinicians with modern tools."

- Jane Rendall, Managing Director at Sectra, UK and Ireland.

 

Spotlight

This is a short powerpoint presentation of my paper on Health Information Technology.  Hope you find it informative.

Spotlight

This is a short powerpoint presentation of my paper on Health Information Technology.  Hope you find it informative.

Related News

HEALTH TECHNOLOGY

Dialyze Direct Partners with CommuniCare Health to Provide On-Site Dialysis

Dialyze Direct | July 28, 2022

Dialyze Direct, the nation’s leading provider of home hemodialysis services in Skilled Nursing Facilities. announced it has partnered with CommuniCare Family of Companies, one of the nation’s largest post-acute care providers, to conduct onsite hemodialysis services at its facilities around the U.S. Founded in 1984 on the philosophy of “Serving with Pride,” CommuniCare’s standard of excellence, which focuses on patient care and quality of life, mirrors Dialyze Direct’s mission to change the dialysis industry by pioneering customized, gentler care proven to positively impact patients’ prognoses and quality of life. Dialyze Direct’s continued growth with like-minded healthcare providers has further solidified the company’s position as the foremost home hemodialysis provider to SNFs in the United States. “The ultimate goal of healthcare is to provide services that benefit our clients but also to ensure those services save or significantly prolong lives. As a result, we approach partnerships with the understanding that both parties share a common patient-first philosophy. We are pleased to bring our onsite dialysis offerings to CommuniCare’s facilities and join forces with a fellow provider that also views patient comfort and care as the cornerstone of their business model.” Dialyze Direct’s Chairman and Co-Founder Henry Kauftheil Dialyze Direct recently announced its acquisition of Chicago-based RenPro Renal Services, which provided dialysis services to patients in SNFs in Illinois, Indiana, Ohio and Kentucky. Earlier this year, the company completed its acquisition of Compass Home Dialysis, a regional SNF dialysis provider in Pennsylvania, and at the end of 2021, the company acquired Renew Dialysis, a regional SNF dialysis provider in Ohio and Virginia. “Providing our residents with a better quality of life is what we strive for at CommuniCare,” said Ronald Wilheim, President of CommuniCare. “We are proud to partner with Dialyze Direct and that through this partnership we have another opportunity to raise the bar and innovate our level of care.” Dialyze Direct now offers onsite dialysis services in more than 170 SNFs in Florida, Illinois, Indiana, Kentucky, Maryland, Missouri, New Jersey, New York, Ohio, Pennsylvania, Tennessee, Texas, Virginia, and West Virginia. About Dialyze Direct Founded in 2015, Dialyze Direct is a leading kidney care innovation company that seeks breakthrough solutions for patients suffering from kidney disease. With a mission to build the next generation of kidney care, Dialyze Direct leverages its leading nephrology specialists to develop new methods and technology to evolve the treatment options nephrologists have at their disposal. Dialyze Direct pioneered significant changes to the existing treatment model for dialysis patients in skilled nursing facilities (SNFs), in which many of the most medically challenging subsets of dialysis patients reside, and has grown to become the nation’s largest provider of home dialysis in the SNF setting. Dialyze Direct’s innovative staff-assisted home hemodialysis treatment model entails a gentler, personalized treatment plan comprised of meticulously crafted protocols designed to tackle the unique fluid management challenges of geriatric dialysis patients, resulting in increased overall patient health and reduced hospitalizations while substantially decreasing costs for payors. Dialyze Direct currently operates in 13 states with new operations launching soon in additional states. About CommuniCare Health Services CommuniCare Health Services was founded in 1984 and is headquartered in Cincinnati, Ohio. The company currently operates more than 110 healthcare and rehabilitation centers in seven states. Our centers focus on patient-centered care plans and provide specialized programing in cardiac, pulmonology, memory care & dementia, amputee and behavioral health. Our expert physicians and nurses provide care for the most medically complex residents.

Read More

HEALTHTECH SECURITY

Medtronic Extravascular ICD meets global pivotal clinical trial's safety and effectiveness endpoints

Medtronic plc | August 29, 2022

Medtronic plc a global leader in healthcare technology, today announced that its investigational EV ICD™ System – a first-of-its-kind defibrillator with the lead placed under the breastbone, outside of the heart and veins – achieved a defibrillation success rate of 98.7% and met its safety endpoints in a global clinical trial. Findings from the Extravascular Implantable Cardioverter Defibrillator Pivotal Study were presented as late-breaking science today at the European Society of Cardiology Congress 2022 in Barcelona and simultaneously published in The New England Journal of Medicine. Worldwide, the EV ICD system is investigational and not yet approved for sale or distribution. The Medtronic EV ICD system is designed to treat dangerously fast heart rhythms that can lead to sudden cardiac arrest while avoiding certain risks of traditional, transvenous ICDs because its lead (thin wire) is placed outside the heart and veins, under the breastbone (sternum) using a minimally invasive approach. Placing the lead in this location is designed to help avoid long-term complications that may be associated with leads in the heart and veins, such as vessel occlusion and risks for blood infections. The lead is connected to a device that is implanted below the left armpit. Clinical trial participants received the same therapies provided by traditional ICDs, including defibrillation, anti-tachycardia pacing (ATP), and back-up pacing therapies with this single implanted device that is similar in size, shape, and longevity to traditional ICDs. "We are very encouraged by the high defibrillation effectiveness and strong safety profile of the EV ICD system seen in the study, as we look to deliver less-invasive treatment options for patients at risk of sudden cardiac arrest. These results demonstrate the potential for this novel technology to be used as a safe, successful approach for patients with life-threatening arrhythmias." Ian Crozier, MB, CHB, M.D., Christchurch Hospital, Christchurch, New Zealand, who presented the results at ESC Congress 2022 At six months, 25 major complications were observed in 23 of 316 patients who underwent an implant attempt (7.3%). Twenty-nine patients experienced inappropriate shocks (9.7%, average 10.6 months follow up), most commonly due to P-wave oversensing, which was more frequent in patients implanted early in the study and less frequent among patients implanted later in the study. "These pivotal data mark the start of a new era in ICD therapy for patients who are at significant risk of dangerously fast heart rhythms," said Alan Cheng, M.D., chief medical officer of the Cardiac Rhythm Management business, which is part of the Cardiovascular Portfolio at Medtronic. "Today's findings are an important clinical milestone toward our goal of delivering a one-system, one-procedure extravascular ICD solution that prevents sudden cardiac arrest while improving the patient experience with a smaller device and moving the lead out of the veins and placing it under the breastbone. The EV ICD system retains the benefits of a completely extravascular system while providing ATP, pause prevention pacing and low defibrillation energy." The EV ICD Pivotal study is a prospective, multicenter, single-arm, non-randomized, pre-market clinical study that assessed the safety and effectiveness of the Medtronic EV ICD system for patients at risk of sudden cardiac death. The EV ICD Pivotal study enrolled 356 patients at 46 sites in 17 countries in North America, Europe, the Middle East, Asia, Australia and New Zealand. Medtronic has received FDA approval for a Continued Access Study while the agency reviews the company's EV ICD pre-market application. About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for all. In everything we do, we are engineering the extraordinary.

Read More

HEALTH TECHNOLOGY

Sense and TECOmedical Sign Distribution Agreement for Germany, Austria, Switzerland

Sense Biodetection | September 02, 2022

Global molecular diagnostics innovator, Sense Biodetection announced it has entered into a strategic agreement with TECOmedical for the non-exclusive distribution of Sense’s Veros COVID-19, the first test on the rapid, instrument-free, point-of-care Veros molecular testing platform. The self-contained, single-use Veros COVID-19 product produces PCR-quality results in about 15 minutes, unconstrained by a reader or need for external power. TECOmedical, a Eurobio Scientific Company, is a leading specialty medical distributor with proven success developing new markets with innovative technology. Effective immediately in Germany and Austria, and pending regulatory approval in Switzerland, the agreement is the latest in Sense’s planned EU distribution partnerships as it commercializes its Veros platform. “We are delighted to partner with TECOmedical to bring Veros COVID-19 to the market, building on the impressive reputation that TECOmedical has established with their customers,” stated Ryan Roberts, Chief Commercial Officer of Sense. “We’re optimistic that by adding the instrument-free Veros COVID-19 to their diagnostic portfolio, TECOmedical’s customers will be able to take advantage of a laboratory-quality molecular test that can enable improved access and faster diagnosis, helping them to provide exceptional care for their patients right at the point of use.” “We are always looking for innovative technologies that address an unmet need. Being able to offer an instrument free, PCR-quality result in minutes right at the Point of Care reflects our commitment to customers to bring solutions that help them overcome limitations of existing technologies and improve care. We are excited to launch Veros COVID-19 now and are eagerly anticipating an expanded Veros test menu in the future.” Marieluise Wippermann, CEO of TECOmedical Veros is the first and only instrument-free, single-use, rapid, point-of-care molecular diagnostic testing platform that produces lab-quality results in about 15 minutes. Using a proprietary, rapid molecular amplification technology, Veros aims to help to improve access to rapid, highly accurate, point of care testing for many more people, and help reduce the spread of COVID-19 with faster, more precise diagnoses. Veros COVID-19’s clinical performance was established in one of the most comprehensive clinical trials in COVID-19 diagnostic testing conducted to date. The multicentre study prospectively enrolled nearly 300 evaluable subjects during both the Delta and Omicron variant surges of the pandemic. All study sites represented near-patient testing / point-of-care environments, with all test operators reporting no prior formal laboratory training or experience. 100% of operators agreed the Veros COVID-19 was easy-to-use, read and understand the results, with minimal hands-on time required from start to finish. As the virus continues to evolve, Veros COVID-19 has maintained 100% conservation in all Variants of Interest and Concern identified to date by WHO and the US CDC, including all Omicron sub-variants. About Sense Biodetection Sense Biodetection is a global molecular diagnostics company focused on empowering patients and transforming healthcare access and affordability by bringing lab-quality results through easy-to-use, rapid, disposable molecular tests without the constraints of an instrument. The company's Veros product platform will enable widespread testing to enhance patient access, improve patient health and lower systemic healthcare costs. Backed by respected investors, such as Koch Disruptive Technologies, Cambridge Innovation Capital, Earlybird Health and Mercia Asset Management, Sense has launched its first product, Veros COVID-19, and is growing rapidly while building a portfolio of tests for other diseases. About TECOmedical The Swiss-based TECOmedical Group, a Eurobio Scientific company, with subsidiaries in Germany and Austria is a leading provider of in-vitro specialty test systems in medical diagnostic, based on Immunosorbent, Immunofluorescence and Molecular methodologies.

Read More